|
6/18/2013 4:05:30 PM
|
|
|
6/18/2013 4:02:13 PM
|
Biodel Announces Proposed Public Offering Of Common Stock
|
|
6/6/2013 6:13:15 AM
|
|
|
6/6/2013 6:02:51 AM
|
Biodel Plans To Submit NDA To FDA In 2015 For Novel Glucagon Rescue Device To Treat Severe Hypoglycemia
|
|
5/8/2013 7:36:18 AM
|
Biodel Q2 Loss/shr Narrows To $0.37 From $0.45 Last Year
|
|
5/8/2013 7:01:13 AM
|
|
|
3/28/2013 6:01:01 AM
|
Biodel Completes Enrollment In Phase 2 Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
|
|
2/12/2013 4:34:53 PM
|
Biodel Posts Q1 Loss Per Share Of $0.26 Vs. Loss $0.47 Year Ago
|
|
2/12/2013 3:00:22 PM
|
|
|
2/11/2013 2:02:07 PM
|
|
|
1/25/2013 4:30:56 AM
|
|
|
1/24/2013 6:03:26 AM
|
Biodel Reveals Positive Top-Line Results From Clinical Study Of Ultra-Rapid-Acting Insulin Analog Candidates
|
|
12/18/2012 7:01:23 AM
|
|
|
12/18/2012 6:01:45 AM
|
Biodel Posts Q4 Loss/Share Of $0.42 Vs. Profit $0.43 Last Year
|
|
12/6/2012 4:39:41 PM
|
Biodel Says FDA Grants Orphan Drug Designation To Glucagon For Prevention Of Hypoglycemia In CHI Population
|
|
9/24/2012 6:31:53 AM
|
Biodel Awarded NIH Grant To Develop Glucagon Formulations For Use In Artificial Pancreas
|
|
8/8/2012 4:43:46 PM
|
Biodel Posts Q3 Loss Per Share Of $0.52 Vs. Loss $0.48 Year Ago
|
|
8/8/2012 3:00:30 PM
|
|
|
7/26/2012 6:08:56 AM
|
Biodel Gets NIH Grant To Develop Concentrated Ultra-Rapid-Acting Insulin Formulations For Use In Artificial Pancreas
|
|
7/13/2012 10:30:23 AM
|
|